On The Therapeutic Potential of Tocilizumab in IL-6-Positive Cancers
IL-6 is an immune signaller misappropriated by many cancer types to engender immune senescence and proliferative auto-signalling. Disrupting this misappropriation can help overcome IL-6-positive cancers.